However, minimal activities were achieved against tumours harbouring actionable aberration(s) in FGFR1‐3, including FGFR1‐amplified SqCLC and gastric adenocarcinoma with FGFR2 polysomy or gene amplification.183, 184. The gene discussed is FGFR2; the disease is gastric adenocarcinoma.